Beta Bionics, Inc. (BBNX) SEC Filings & Earnings Calls

Dilution from equity offering may pressure stock price.

“Form of Pre-Funded Warrant included in the filing.”

Regulatory clearance is positive but commercialization and market adoption risks remain.

“Forward-looking statements caution about regulatory approvals, market acceptance, and competition.”

Net loss widening in absolute terms despite revenue growth

“Net loss of $23.4 million compared to $16.9 million in Q2 2025”

Dependence on regulatory approvals for pipeline products (iLet type 2 diabetes, Mint patch pump)

“subject to regulatory clearance by the FDA; expects to expand iLet's indications for use to adults with type 2 diabetes in the U.S. around mid-year 2027, subject to regulatory clearance”

Ongoing quality system remediation costs

“quality system remediation... in response to the FDA Form 483 and Warning Letter” · word for word

Regulatory clearance dependency

“We expect Mint to expand the addressable insulin delivery market... Subject to receiving FDA 510(k) clearance as an alternate controller enabled (ACE) pump, we expect to fully commercialize Mint by the end of the second quarter of 2027.” · word for word

Channel mix impact on gross margin

“iLet sales in the PBP channel are generally expected to then start generating cumulative positive gross margin for us following the third month the user utilizes the iLet and continues to purchase single-use products.” · word for word

Operating loss trajectory

“Net loss $ (23,403 ) for the three months ended June 30, 2026, compared to $ (16,869 ) for the three months ended June 30, 2025.”

FDA regulatory clearance risk for Mint

“Mint commercialization subject to FDA clearance; timeline updated based on FDA responses.”

Sequential decline in new patient starts may indicate seasonal or competitive headwinds.

“New patient starts declined by at least 10% but less than 20% sequentially versus the fourth quarter of 2025.” · word for word

Still generating significant operating losses, though improving as a percentage of sales.

“Loss from operations of $24.3 million, or negative 88% of sales.” · word for word

FDA Warning Letter and quality system remediation

“In January 2026, we received a Warning Letter ('Warning Letter') from the FDA following inspection of our facility in Irvine, California that occurred from June 9, 2025 through June 26, 2025.” · word for word

Channel mix shift to PBP may cause near-term gross margin volatility

“As a result of a small amount of revenue recognized at or around the date the iLet is sold in the PBP channel, we absorb initial negative gross margin.” · word for word

Dependence on third-party payor reimbursement

“Our revenue and results of operations may be impacted if we are unable to secure sufficient coverage or reimbursement from third-party payors for our current or future products.” · word for word

Credit Quality Deterioration

“Nonperforming loans compared to loans held for investment increased 0.82% to 1.24% as of December 31, 2025, while the ratio of nonperforming assets compared to total assets increased 0.70% to 1.09% compared to the prior year, December 31, 2024.”

Recession Demand Risk

“Since the sale of the iLet to a new PWD will be generally dependent on the availability of third-party reimbursement and will require the patient to make a significant co-payment, an economic downturn on our potential customers could reduce the referrals generated by our sales force and thereby reduce our customer orders.” · word for word

NOL Limitation Risk

“As of December 31, 2025, we had U.S. federal NOL carryforwards of $240.8 million... under Sections 382 and 383... if a corporation undergoes an 'ownership change'... the corporation's ability to use its pre-change NOL carryforwards... may be limited.” · word for word

Patent Term Risk

“Given the amount of time required for the development, testing and regulatory review of products, patents protecting such product candidates might expire before or shortly after such products are commercialized.” · word for word

Still generating significant operating losses, though improving as a percentage of sales.

“Full year loss from operations of $71.7 million, or negative 72% of sales.”

Dependence on PBP channel expansion for margin improvement; any disruption could impact profitability.

“PBP channel net sales grew 287% YoY, but still represents a smaller portion of total revenue.”

FDA Warning Letter could lead to further regulatory action, including potential enforcement if deficiencies not resolved

“FDA Warning Letter; company cannot assure FDA will be satisfied with response; additional legal/regulatory action possible”

Potential delay or disruption to Mint commercialization if FDA issues further restrictions

“Company does not expect impact on Mint timeline, but risk remains if FDA escalates”

Preliminary results subject to audit; competitive market with established players.

“Preliminary, unaudited; competition from Medtronic, Tandem, Insulet.”

Customer Concentration

“For the nine months ended September 30, 2025, our top four DME distributors represented approximately 52% of our total sales.” · word for word

Single Source Supplier Dependency

“Unomedical, PMC and Maxon are our only suppliers of infusion sets, cartridge connections and pump motors, respectively.” · word for word

Tariff Exposure

“We source significant quantities of the iLet’s components from international suppliers, with substantial reliance on foreign manufacturers, including China.” · word for word

Cybersecurity Vulnerability

“The FDA has warned that insulin pumps may have cybersecurity vulnerabilities and could be manipulated by hackers, causing danger to PWD.” · word for word

Operating losses persist despite revenue growth; adjusted EBITDA negative $12.2M in Q3.

“Loss from operations of $17.0 million... Adjusted EBITDA of negative $12.2 million.” · word for word

Dependence on PBP channel reimbursement expansion; formulary agreements still being implemented with health plans.

“Beta Bionics is actively working with the health plans that partner with those PBMs to drive coverage of iLet under their pharmacy benefit.” · word for word

Bihormonal system development still early stage; feasibility trial in New Zealand not yet initiated.

“In the fourth quarter of 2025, Beta Bionics expects to initiate a feasibility trial in New Zealand to test the bihormonal system.” · word for word